COMT Inhibitors/Rasagiline; Oral Selegiline Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

When these two medicines are taken together at high dosages, your body may not be able to process certain body chemicals (e.g. epinephrine) properly.

What might happen:

You may experience a faster heart rate and/or an increase in blood pressure.

What you should do about this interaction:

Let your your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these two medicines together. At normal dosages, these medicines can be used together. They may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Comtess (entacapone) UK summary of product characteristics. Orion Pharma, UK September 16, 1998.
  • 2.Tasmar (tolcapone) US prescribing information. Valeant Pharmaceuticals International May, 2013.
  • 3.Comtan (entacapone) US prescribing information. Orion Corporation February, 2016.
  • 4.Comtan (entacapone) Canadian prescribing information. Novartis Pharmaceuticals Canada Inc. March, 2006.
  • 5.Tasmar (tolcapone) UK summary of product characteristics. Valeant Pharmaceuticals Ltd. Januar 11, 2006.
  • 6.Azilect (rasagiline) US prescribing information. Teva Neurosciences Inc. June, 2020.
  • 7.A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005 Feb;62(2):241-8.
  • 8.Eldepryl (selegiline) US prescribing information. Somerset Pharmaceuticals February, 1997.
  • 9.Ongentys (opicapone) Middle East prescribing information. Bial-Portela and Ca, S.A. 2018.
  • 10.Ongentys (opicapone) US prescribing information. Neurocrine Biosciences, Inc. April, 2020.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.